ATE480545T1 - Imidazo-verbindungen - Google Patents

Imidazo-verbindungen

Info

Publication number
ATE480545T1
ATE480545T1 AT07728052T AT07728052T ATE480545T1 AT E480545 T1 ATE480545 T1 AT E480545T1 AT 07728052 T AT07728052 T AT 07728052T AT 07728052 T AT07728052 T AT 07728052T AT E480545 T1 ATE480545 T1 AT E480545T1
Authority
AT
Austria
Prior art keywords
imidazo compounds
imidazo
compounds
Prior art date
Application number
AT07728052T
Other languages
English (en)
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Aleksandar Stojanovic
Christiane Marti
Stjepan Jelakovic
Stefan Stutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE480545T1 publication Critical patent/ATE480545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT07728052T 2006-04-12 2007-04-12 Imidazo-verbindungen ATE480545T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH6202006 2006-04-12
PCT/EP2007/053585 WO2007116099A1 (en) 2006-04-12 2007-04-12 Imidazo compounds

Publications (1)

Publication Number Publication Date
ATE480545T1 true ATE480545T1 (de) 2010-09-15

Family

ID=38462029

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07728052T ATE480545T1 (de) 2006-04-12 2007-04-12 Imidazo-verbindungen
AT07728054T ATE463498T1 (de) 2006-04-12 2007-04-12 Imidazo-verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07728054T ATE463498T1 (de) 2006-04-12 2007-04-12 Imidazo-verbindungen

Country Status (15)

Country Link
US (3) US7879847B2 (de)
EP (2) EP2007770B1 (de)
JP (2) JP2009534319A (de)
CN (2) CN101421277A (de)
AR (1) AR060590A1 (de)
AT (2) ATE480545T1 (de)
BR (2) BRPI0710614A2 (de)
CA (2) CA2649213A1 (de)
DE (2) DE602007009074D1 (de)
ES (2) ES2352358T3 (de)
IL (2) IL194584A0 (de)
PL (2) PL2007771T3 (de)
PT (2) PT2007770E (de)
TW (1) TW200808813A (de)
WO (2) WO2007116099A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511621A (pt) * 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
AR056888A1 (es) * 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
MA33364B1 (fr) 2009-05-28 2012-06-01 Novartis Ag Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
CA2763572C (en) 2009-05-28 2017-10-17 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2013008164A2 (en) 2011-07-08 2013-01-17 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2014126979A1 (en) 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
ES2684050T3 (es) * 2014-07-24 2018-10-01 Boehringer Ingelheim International Gmbh Inhibidores de aldosterona sintasa
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP3887388A1 (de) 2018-11-27 2021-10-06 Novartis AG Zyklische peptide als proprotein-konvertase-subtilisin-/kexin typ 9 (pcsk9) zur behandlung von stoffwechselstörungen
PY1998404A (es) 2018-11-27 2021-06-17 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
US11958818B2 (en) 2019-05-01 2024-04-16 Boehringer Ingelheim International Gmbh (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
WO2023114170A1 (en) 2021-12-14 2023-06-22 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0670064B2 (ja) * 1986-12-08 1994-09-07 三井石油化学工業株式会社 二環性イミダゾ−ル誘導体
AU6015796A (en) * 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
HUP0301335A3 (en) 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
ATE335744T1 (de) * 2002-08-07 2006-09-15 Novartis Pharma Gmbh Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
US7612088B2 (en) 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
BRPI0511621A (pt) * 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
TW200608978A (en) 2004-05-28 2006-03-16 Speedel Experimenta Ag Organic compounds
AR049711A1 (es) * 2004-07-09 2006-08-30 Speedel Experimenta Ag Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR056888A1 (es) * 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds

Also Published As

Publication number Publication date
EP2007771B1 (de) 2010-04-07
JP2009533395A (ja) 2009-09-17
US20090192144A1 (en) 2009-07-30
WO2007116101A1 (en) 2007-10-18
PL2007771T3 (pl) 2010-10-29
CN101421279A (zh) 2009-04-29
BRPI0711540A2 (pt) 2011-11-01
EP2007770B1 (de) 2010-09-08
CA2649213A1 (en) 2007-10-18
CA2649217A1 (en) 2007-10-18
PL2007770T3 (pl) 2011-03-31
WO2007116099A1 (en) 2007-10-18
PT2007771E (pt) 2010-05-11
ATE463498T1 (de) 2010-04-15
EP2007770A1 (de) 2008-12-31
ES2352358T3 (es) 2011-02-17
AR060590A1 (es) 2008-07-02
TW200808813A (en) 2008-02-16
CN101421277A (zh) 2009-04-29
JP5260496B2 (ja) 2013-08-14
US8138176B2 (en) 2012-03-20
US20110092492A1 (en) 2011-04-21
DE602007009074D1 (de) 2010-10-21
CN101421279B (zh) 2012-08-15
EP2007771A1 (de) 2008-12-31
JP2009534319A (ja) 2009-09-24
DE602007005788D1 (de) 2010-05-20
PT2007770E (pt) 2010-10-21
ES2342689T3 (es) 2010-07-12
IL194584A0 (en) 2009-08-03
BRPI0710614A2 (pt) 2011-08-16
IL194583A0 (en) 2009-08-03
US7879847B2 (en) 2011-02-01
US20090192149A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
FIC20220006I1 (fi) Tafasitamabi
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
ATE480545T1 (de) Imidazo-verbindungen
ATE524477T1 (de) Aziridinylepothilonverbindungen
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0813500A2 (pt) Compostos antivirais
BRPI0718874A2 (pt) Compostos orgânicos
BRPI0714512A2 (pt) Compostos químicos
NO20084803L (no) organiske forbindelser
BRPI0718478A2 (pt) Compostos orgânicos
BRPI0821086A2 (pt) Compostos inseticidas
AT504580A3 (de) Scan-einrichtung
DE602006021235D1 (de) Kristallglasgegenstand
BRPI0717070A2 (pt) compostos de tiofeno pirazolopirimidina
BRPI0811264A2 (pt) Compostos
BRPI0712902A2 (pt) compostos orgânicos
DE502007001629D1 (de) Rfahren
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007000501D1 (de) Breitbandrichtkoppler
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0815181A2 (pt) Compostos
DE112007003147A5 (de) Rohr-Biegevorrichtung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2007770

Country of ref document: EP